Travere Therapeutics: Positive Trial Results of its Product Sparsentan in Treating IgA Nephropathy

Travere Therapeutics Sparsentan for IgAN Positive Results
Phase 3 PROTECT Study of Travere Therapeutics (TVTX) product sparsentan for the treatment of IgA nephropathy (IgAN) demonstrated positive topline interim results. The PROTECT Study met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater than a threefold reduction of proteinuria from baseline after 36 weeks of treatment . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.